Upfront combination therapy in anti-melanoma differentiation-associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease

被引：0
作者：
Tseng, Chih-Wei [1 ,2 ]
机构：
[1] Taichung Vet Gen Hosp, Dept Internal Med, Div Allergy Immunol & Rheumatol, 1650 Taiwan Blvd Sect 4, Taichung 407, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan, Taiwan
来源：
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES | 2024年 / 27卷 / 06期
关键词：
DERMATOMYOSITIS; MORTALITY; UPDATE;
D O I：
10.1111/1756-185X.15208
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 25 条
[1]   Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis [J].
Abe, Yoshiyuki ;
Matsushita, Masakazu ;
Tada, Kurisu ;
Yamaji, Ken ;
Takasaki, Yoshinari ;
Tamura, Naoto .
RHEUMATOLOGY, 2017, 56 (09) :1492-1497
[2]  
Beasley MB, 2010, ARCH PATHOL LAB MED, V134, P719, DOI 10.1043/1543-2165-134.5.719
[3]   Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease [J].
Chen, Xixia ;
Jiang, Wei ;
Jin, Qiwen ;
Peng, Qinglin ;
Zhang, Lu ;
Lin, Sang ;
Lu, Xin ;
Liu, Min ;
Wang, Yuli ;
Song, Aiping ;
Feng, Ruie ;
Wang, Guochun .
RMD OPEN, 2023, 9 (02)
[4]   Treating dermatomyositis anti-melanoma differentiation-associated gene 5 antibody disease. A true rheumatologic urgency [J].
Gardner, Gregory C. .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (01)
[5]   Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease [J].
Gono, Takahisa ;
Masui, Kenichi ;
Nishina, Naoshi ;
Kawaguchi, Yasushi ;
Kawakami, Atsushi ;
Ikeda, Kei ;
Kirino, Yohei ;
Sugiyama, Yumiko ;
Tanino, Yoshinori ;
Nunokawa, Takahiro ;
Kaneko, Yuko ;
Sato, Shinji ;
Asakawa, Katsuaki ;
Ukichi, Taro ;
Kaieda, Shinjiro ;
Naniwa, Taio ;
Okano, Yutaka ;
Kuwana, Masataka .
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (04) :677-686
[6]   Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease [J].
Hata, Kenichiro ;
Kotani, Takuya ;
Matsuda, Shogo ;
Fujiki, Youhei ;
Suzuka, Takayasu ;
Kiboshi, Takao ;
Wada, Yumiko ;
Shiba, Hideyuki ;
Shoda, Takeshi ;
Kagitani, Maki ;
Takeuchi, Tohru .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (01)
[7]   Pulmonary pathology of severe acute respiratory syndrome in Toronto [J].
Hwang, DM ;
Chamberlain, DW ;
Poutanen, SM ;
Low, DE ;
Asa, SL ;
Butany, J .
MODERN PATHOLOGY, 2005, 18 (01) :1-10
[8]   SARS-CoV-2 organising pneumonia: 'Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?' [J].
Kory, Pierre ;
Kanne, Jeffrey P. .
BMJ OPEN RESPIRATORY RESEARCH, 2020, 7 (01)
[9]   Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis [J].
Kurasawa, Kazuhiro ;
Arai, Satoko ;
Namiki, Yumeko ;
Tanaka, Ayae ;
Takamura, Yuta ;
Owada, Takayoshi ;
Arima, Masafumi ;
Maezawa, Reika .
RHEUMATOLOGY, 2018, 57 (12) :2114-2119
[10]   Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: a single center retrospective cohort study [J].
Lee, Ju Kwang ;
Ahn, Yura ;
Noh, Han Na ;
Lee, Sang Min ;
Yoo, Bin ;
Lee, Chang-Keun ;
Kim, Yong-Gil ;
Hong, Seokchan ;
Ahn, Soo Min ;
Kim, Ho Cheol .
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) :4797-4807
123